The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Neue, effektive Therapieoptionen für Patienten mit Psoriasis stehen kurz vor der Zulassung. Dabei setzen Therapien gegen die Interleukine (IL)-17 und -23 neue Maßstäbe in der Wirksamkeit. Ihre Effektivität und Sicherheit wurde in zahlreichen Studien untersucht.
Neben den in der letzten Ausgabe vorgestellten Anti-Interleukin(IL)-17- und Anti-IL-23-Antikörpern befinden sich auch mehrere neue kleinmolekulare Substanzen zur Behandlung der Psoriasis in der Entwicklung, darunter Phosphodiesterase-IV- und Januskinase-Inhibitoren.
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.